Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 17/20 | 0.59 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5784677 | 0.93 | AVPR2 (0.56) | AVPR2AVPR1AP2RX7 | |
| SCHEMBL5782835 | 0.91 | AVPR2 (0.67) | AVPR2AVPR1AP2RX7KDM4E | |
| SCHEMBL5783502 | 0.91 | AVPR2 (0.56) | AVPR2AVPR1AP2RX7HTR2C | |
| SCHEMBL5784841 | 0.90 | AVPR2 (0.55) | AVPR2AVPR1AP2RX7HTR2C | |
| SCHEMBL5784636 | 0.90 | AVPR2 (0.54) | AVPR2AVPR1AP2RX7 | |
| SCHEMBL5783636 | 0.89 | AVPR2 (0.64) | AVPR2AVPR1AP2RX7KDM4EHTT | |
| SCHEMBL5784511 | 0.87 | AVPR2 (0.58) | AVPR2AVPR1AP2RX7 | |
| SCHEMBL5891365 | 0.85 | AVPR2 (0.54) | AVPR2AVPR1AP2RX7GAA | |
| SCHEMBL5816735 | 0.85 | AVPR2 (0.65) | AVPR2AVPR1A | |
| SCHEMBL5891138 | 0.84 | AVPR2 (0.53) | AVPR2KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900200-B2 | Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-05-31 | — | — | US | claimed |
| EP-1377583-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | claimed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-6900200-B2 | Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1377583-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR2 45/4885AVPR1A 30/4885P2RX7 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.